British Journal of Pharmacology · 1972 · 18 citations · 15 references
MedicineNeurosciencePharmacologyNeuropharmacologyPharmacodynamicsPsychopharmacologySerotonergic PharmacologyNeurophysiology Of TremorPharmacological Treatment Of TremorTremor Pathophysiology
Drugs which reduce central catecholamine activity increased the tremorigenic action physostigmine (0.25 mg/kg) in the rat. The potentiation of physostigmine tremor induced by these neuroleptic drugs was quantitated measuring the ratio of post- to prephysostigmine motor activity; this ratio may be useful index of catecholamine/cholinergic balance. Of the compounds tested, chlorpromazine HC1 (15 mg/kg) and reserpine (10 mg/kg) had the greatest potentiating effect on the tremor-producing action of physostigmine. LDOPA (500 mg/kg) reduced the tremor induced by physostigmine in rats pre-treated with reserpine, but not in rats pre-treated with chlorpromazine.
15
The pathogenesis of Parkinson's disease: a new hypothesis.
André Barbeau · PubMed · 1962 · 345 citations
Cholinergic-Anticholinergic Antagonism in Parkinsonism
Roger C. Duvoisin · Archives of Neurology · 1967 · 342 citations
Medicine, Neurology, Pharmacology +12
Drug-Induced Extrapyramidal Reactions
Patrick L. McGeer · JAMA · 1961 · 202 citations
Biochemical and pharmacologic effects of α-methyltyrosine in man
Karl Engelman, David L. Horwitz, Eric Jéquier et al. · Journal of Clinical Investigation · 1968 · 170 citations · Full text